A Review of Hormone and Non-Hormonal Therapy Options for the Treatment of Menopause
暂无分享,去创建一个
J. Manson | M. Allison | Tracy E. Madsen | M. Stefanick | Talia Sobel | Seraphina Negash | Tara Shrout Allen | S. Negash
[1] R. Thurston,et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study , 2023, The Lancet.
[2] R. Lobo. The 2022 hormone therapy position statement of The North American Menopause Society. , 2022, Menopause.
[3] G. Neal-Perry,et al. Phase 3 Study of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause [A132] , 2022, Obstetrics & Gynecology.
[4] J. Manson,et al. Serum follicle stimulating hormone and five-year change in adiposity in healthy postmenopausal women. , 2022, The Journal of clinical endocrinology and metabolism.
[5] Maya B. Mathur,et al. Menopausal hormone therapy and women’s health: An umbrella review , 2021, PLoS medicine.
[6] D. Poyares,et al. Hot flashes, insomnia, and the reproductive stages: a cross-sectional observation of women from the EPISONO study. , 2021, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.
[7] R. Beverly,et al. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women , 2021 .
[8] Theresa M. Beckie,et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. , 2020, Circulation.
[9] James B. Young,et al. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA) , 2020, Menopause.
[10] J. Manson,et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. , 2020, JAMA.
[11] Louis A. Pagliaro,et al. Paroxetine , 2020, Reactions Weekly.
[12] K. Matthews,et al. Does mid-life aging impact women's sleep duration, continuity, and timing?: A longitudinal analysis from the Study of Women's Health Across the Nation. , 2020, Sleep.
[13] C. Champagne,et al. Racial differences in body composition and cardiometabolic risk during the menopause transition: a prospective, observational cohort study. , 2020, American journal of obstetrics and gynecology.
[14] V. Beral,et al. Menopausal hormone therapy and 20-year breast cancer mortality , 2019, The Lancet.
[15] K. Matthews,et al. The menopause transition and women's health at midlife: a progress report from the Study of Women's Health Across the Nation (SWAN) , 2019, Menopause.
[16] V. Beral,et al. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence , 2019, The Lancet.
[17] D. Grigoraș,et al. Surgically Induced Menopause—A Practical Review of Literature , 2019, Medicina.
[18] A. Graziottin,et al. Hormone therapy for first-line management of menopausal symptoms: Practical recommendations , 2019, Women's health.
[19] J. Manson,et al. Association of Normal-Weight Central Obesity With All-Cause and Cause-Specific Mortality Among Postmenopausal Women , 2019, JAMA network open.
[20] J. Hippisley-Cox,et al. Anticholinergic Drug Exposure and the Risk of Dementia , 2019, JAMA internal medicine.
[21] J. Manson,et al. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? , 2019, Menopause.
[22] Y. Vinogradova. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases , 2019, British Medical Journal.
[23] J. Hippisley-Cox,et al. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases , 2019, British Medical Journal.
[24] S. Crawford,et al. Menopausal hormone therapy trends before versus after 2002: impact of the Women's Health Initiative Study Results. , 2019, Menopause.
[25] R. Thurston,et al. Cardiovascular Implications of the Menopause Transition: Endogenous Sex Hormones and Vasomotor Symptoms. , 2018, Obstetrics and gynecology clinics of North America.
[26] A. Dobson,et al. Relationships between intensity, duration, cumulative dose, and timing of smoking with age at menopause: A pooled analysis of individual data from 17 observational studies , 2018, PLoS medicine.
[27] P. Spritzer,et al. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis. , 2018, Thrombosis research.
[28] Sanjiv J. Shah,et al. Relation of Sex Hormone Levels With Prevalent and 10-Year Change in Aortic Distensibility Assessed by MRI: The Multi-Ethnic Study of Atherosclerosis , 2018, American journal of hypertension.
[29] J. Manson,et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials , 2017, JAMA.
[30] J. Manson,et al. The 2017 hormone therapy position statement of The North American Menopause Society , 2017, Menopause.
[31] P. Tobler,et al. Ovarian hormones and obesity. , 2017, Human reproduction update.
[32] J. Eden. The endometrial and breast safety of menopausal hormone therapy containing micronised progesterone: A short review , 2017, The Australian & New Zealand journal of obstetrics & gynaecology.
[33] A. Grauer,et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. , 2016, The New England journal of medicine.
[34] V. Henderson,et al. Cognitive effects of estradiol after menopause , 2016, Neurology.
[35] Wendy J Mack,et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. , 2016, The New England journal of medicine.
[36] M. Murad,et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. , 2015, The Journal of clinical endocrinology and metabolism.
[37] Frederick Naftolin,et al. Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study , 2015, PLoS medicine.
[38] S. Crawford,et al. Duration of menopausal vasomotor symptoms over the menopause transition. , 2015, JAMA internal medicine.
[39] Sascha Dublin,et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. , 2015, JAMA internal medicine.
[40] S. Wisniewski,et al. Symptoms of depressed mood, disturbed sleep, and sexual problems in midlife women: cross-sectional data from the Study of Women's Health Across the Nation. , 2015, Journal of women's health.
[41] M. Binkowska. Menopausal hormone therapy and venous thromboembolism , 2014, Przeglad menopauzalny = Menopause review.
[42] K. Moreau,et al. Vascular Aging across the Menopause Transition in Healthy Women , 2014, Advances in vascular medicine.
[43] Lewis H Kuller,et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. , 2013, JAMA.
[44] J. Simon,et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials , 2013, Menopause.
[45] Jennifer G. Robinson,et al. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. , 2013, JAMA internal medicine.
[46] A. Pines. Climacteric Commentaries , 2013, Climacteric : the journal of the International Menopause Society.
[47] A. Trentham-Dietz,et al. A Sustained Decline in Postmenopausal Hormone Use: Results From the National Health and Nutrition Examination Survey, 1999–2010 , 2012, Obstetrics and gynecology.
[48] R. Kane,et al. Benefits and Harms of Pharmacologic Treatment for Urinary Incontinence in Women , 2012, Annals of Internal Medicine.
[49] S. Crawford,et al. Trajectory clustering of estradiol and follicle-stimulating hormone during the menopausal transition among women in the Study of Women's Health across the Nation (SWAN). , 2012, The Journal of clinical endocrinology and metabolism.
[50] P. Sluss,et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. , 2012, The Journal of clinical endocrinology and metabolism.
[51] E. Gold. The timing of the age at which natural menopause occurs. , 2011, Obstetrics and gynecology clinics of North America.
[52] N. Santoro,et al. Reproductive hormones and the menopause transition. , 2011, Obstetrics and gynecology clinics of North America.
[53] D. Carroll,et al. Use of Gabapentin for the Management of Natural or Surgical Menopausal Hot Flashes , 2011, The Annals of pharmacotherapy.
[54] A. Schatzkin,et al. Menopausal Hormone Therapy and Risk of Colorectal Cancer , 2009, Cancer Epidemiology Biomarkers & Prevention.
[55] E. Oger,et al. Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study , 2007, Circulation.
[56] J. Buring,et al. Effects of Conjugated Equine Estrogen on Stroke in the Women’s Health Initiative , 2006, Circulation.
[57] A. Verbeek,et al. Age at Menopause, Cause-Specific Mortality and Total Life Expectancy , 2005, Epidemiology.
[58] L. Patterson,et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy , 2004, Journal of Family Planning and Reproductive Health Care.
[59] JoAnn E Manson,et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. , 2004, JAMA.
[60] L. Thal,et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study , 2004, JAMA.
[61] John Robbins,et al. National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.
[62] R. Chlebowski,et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. , 2004, The New England journal of medicine.
[63] A. LaCroix,et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. , 2003, JAMA.
[64] E. Oger,et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk , 2003, The Lancet.
[65] C. Kooperberg,et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. , 2003, JAMA.
[66] Robert B Wallace,et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.
[67] Leslie Carol Botha. Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women , 2003 .
[68] E. Perez,et al. Pilot evaluation of gabapentin for treating hot flashes. , 2002, Mayo Clinic proceedings.
[69] E. Vittinghoff,et al. Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study , 2000, Annals of Internal Medicine.
[70] J. Carson,et al. Risk of venous thromboembolism in users of hormone replacement therapy , 1996, The Lancet.
[71] J. Manson,et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. , 1996, The New England journal of medicine.
[72] K. Kerlikowske,et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. , 1995, Obstetrics and gynecology.
[73] J. Manson,et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. , 1991, The New England journal of medicine.